Who is sponsoring NCT05675540?

NCT05675540 is sponsored by Guy's and St Thomas' NHS Foundation Trust.

What drugs are being tested in NCT05675540?

Interventions in NCT05675540: Macusense Assessment Software.

What condition does NCT05675540 study?

NCT05675540 studies Wet Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion.

Is NCT05675540 still recruiting?

NCT05675540 is currently status unknown. Last updated 18 May 2023.

Last reviewed 2023-05-18 · How we verify

NCT05675540: AID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Artificial Intelligence Diagnostic Aid

Status unknown Last updated 18 May 2023

What this trial tests

trial testing Macusense Assessment Software in Wet Macular Degeneration in 422 participants. Status unknown.

Timeline

1 June 2023

Primary endpoint
1 December 2023

30 March 2024

Quick facts

Lead sponsor	Guy's and St Thomas' NHS Foundation Trust
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	422
Start date	1 June 2023
Primary completion	1 December 2023
Estimated completion	30 March 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

Macusense Assessment Software

Conditions studied

Wet Macular Degeneration — all drugs for Wet Macular Degeneration →
Diabetic Macular Edema — all drugs for Diabetic Macular Edema →
Retinal Vein Occlusion — all drugs for Retinal Vein Occlusion →

Sponsor

Guy's and St Thomas' NHS Foundation Trust

Who can join

Under 100, any sex, with Wet Macular Degeneration or Diabetic Macular Edema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators have worked with software designers to develop a software that allows us to analyse current adherence to guidelines on Ophthalmic conditions such as Age related Macular Degeneration (AMD), Diabetic Macular Edema (DMO) and Retinal vein occlusion (RVO). National guidelines state that those patients with fluid accumulation in their central macular, meeting criteria, are eligible for injections into the vitreous cavity of the eye (intravitreal).(1) As these condition are common the trial is relevant to the public and patients as future management may be affected by the outcomes of this trial. The investigators will trial the software which uses Artificial Intelligence (AI) algorithms to determine the most suitable review required for patients being managed in clinics, based on 'Vision' and 'Retinal Thickness' demographics. This will be done prospectively, in real time. The question to be addressed is 'Can medical and non-medical practitioners accurately determine treatment and follow-up for patients assisted by an AI clinical decision support system, for the three most common chronic macular diseases - Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Oedema (DMO) and Retinal Vein Occlusion (RVO) - in a safe and clinically cost effective way?' Patients undergoing treatment for at least 12 months are eligible to participate, so long as they are able to provide consent for their data to be used. Participants will have no change to their care during the trial. The study, will take place at Guy's and St. Thomas' NHS FT (GSTT) from where participants will be recruited, and will last approximately 6 months of data collection. The software will be used by the research Fellow, alongside the masked consultant. Therefore the patient pathway and management will not be impacted by this trial. Patients will be consented for data use.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Artificial intelligence for diagnosing exudative age-related macular degeneration.
Kang C, Lo JE, Zhang H, Ng SM, et al · · 2024 · cited 9× · PMID 39417312 · DOI 10.1002/14651858.cd015522.pub2

Verify or expand the search:

Other recruiting trials for Wet Macular Degeneration

Currently open trials in the same condition.

NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting

Other Guy's and St Thomas' NHS Foundation Trust trials

Trials by the same sponsor.

NCT07534917 — Comparing the Effects of Newer Pacemakers and Their Effects on the Heart and Valve Function in the Short-term. · not yet recruiting
NCT07454135 — Mechanisms of Atrial Pathoelectrophysiology in HCM · not yet recruiting
NCT07419945 — Older Kidney Patient Optimisation Pretransplant · NA · not yet recruiting
NCT07309835 — Improving Genetic Medicine for Ethnic Minority Groups · not yet recruiting
NCT07203872 — Inflammation-resolution Therapy in MINST of Periodontal Intrabony Defect: a Pilot Randomised Controlled Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05675540 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guy's and St Thomas' NHS Foundation Trust
Last refreshed: 18 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05675540.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing